Gilead Sciences is a leader in the field of virology treatments. As VP of clinical research for hepatitis, respiratory and emerging viruses at Gilead, Anu Osinusi talked about the pharma company's work in HIV and hepatitis and how her personal background informed her team's work in developing a Covid-19 treatment.
The partnership will primarily focus on the drug DCR-HBVS, an RNA-interference drug that Dicerna is developing for HBV. The deal includes potential milestones of up to $1.47 billion.
Zelis highlights how employers, payers, and consumers are integrating digital tools to manage healthcare costs.
As sales of its hit Hep C drugs decline, Gilead faces an uncertain future. Where to next for a company defined by one blockbuster franchise?
Velano Vascular has developed technology that removes the need for a needle blood draw when someone is in the hospital. Not only does this help those who are afraid of needles, it reduces risk of infection, and it helps to prevent accidental needle pricks with practitioners.
People can do their best to protect themselves from things like hepatitis and HIV by being responsible and aware, but when doctors reuse syringes, all efforts can fall by the wayside. Situations like this have prompted a global campaign from the World Health Organization this week. As NPR reported Tuesday, an 82-year-old celibate Buddhist abbot […]